Tenderwize
Zurück zur Suche

Open house drug discount agreements multienzyme (Lipase, Protease etc.), ATC A09AA02

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Feb 03, 2028 · 524 days left·Open·Supplies·Framework
Registrieren zum SpeichernOpen documents
Structured notice only
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Multienzyme (Lipase, Protease etc.), ATC A09AA02

50/100

Opportunity Score

Needs reviewLow complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

50 / 100

Komplexität

25 / 100

Risikofaktoren

No guaranteed sales; actual revenue depends on prescription volumes and market penetration.

Monthly cut-off deadlines require careful timing; missing the 3rd may delay contract start by up to two months.

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Mar 2028
  • Non-exclusive drug discount agreements for multienzyme products (ATC A09AA02) with AOK Bayern.
  • Open-house model: all eligible pharmaceutical companies may join on identical terms.
Vollständige Zusammenfassung anzeigen

Open-house model for non-exclusive drug discount agreements (Rabattverträge) for multienzymes (Lipase, Protease etc.), ATC A09AA02, with AOK Bayern. The procedure is not a competitive tender but a continuous open-house where any eligible pharmaceutical company can enter identical, non-negotiable agreements. The contract term is from 1 April 2026 to 31 March 2028, with possible early termination if superseded by regular discount contracts. There is no estimated value, and no award criteria since all eligible participants are accepted. The key eligibility requirement is a signed declaration of reliability. Submissions can be in paper (two copies) or electronically with a qualified electronic signature.

Risiken

No guaranteed sales; actual revenue depends on prescription volumes and market penetration.

Monthly cut-off deadlines require careful timing; missing the 3rd may delay contract start by up to two months.

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Eligibility

  • Only pharmaceutical companies are eligible to participate.

Administrative

  • Signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit) must be submitted.
  • Contract and annex 'Festlegung der vertragsgegenständlichen Arzneimittel' must be signed and submitted in duplicate (paper) or with qualified electronic signature.

Anforderungen können unvollständig sein.

Auftraggeber

Ort

München, DEU

Website

www.aok.de

Auftraggeberprofil

Profil öffnen

Kennung

DE811695320

Tätigkeit

Health

Lose (1)

LOT-0001

Open house drug discount agreements multienzyme (Lipase, Protease etc.), ATC A09AA02

Non-exclusive discount agreements for pharmaceutical products containing multienzymes (Lipase, Protease etc.), ATC A09AA02. The agreement is open to all pharmaceutical companies meeting the eligibility criteria. Contracts start on the first of the month following complete submission, with a monthly cut-off on the 3rd. The latest joining date is 3 February 2028.

SuppliesFrameworkEU fundedElectronic submission

Ort

DE212, Germany

Dauer

Mar 2026 - Mar 2028

Kategorie

Pharmaceutical products

Frist

Deadline Feb 03, 2028

Vergabedetails

Veröffentlichungsdatum
15 Feb 2026
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
107164-2026

Dokumente (2)

Vergabedokument 1Einreichungsportal 1

Ähnliche Ausschreibungen

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30